12 weeks Ombitasvir/Paritaprevir-ritonavir + Ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
Digestive and Liver Diseases Feb 18, 2018
Degasperi E, et al. - Safety and efficacy of Ombitasvir/Paritaprevir-ritonavir (OBT/PTV-r) plus Ribavirin (RBV) for 12 weeks were evaluated in real-life hepatitis C virus (HCV)-genotype 4 patients with advanced fibrosis. The authors achieved 100% sustained virological response with 12-weeks of OBT/PTV-r + RBV in HCV-4 patients with the advanced liver disease, including compensated cirrhotics.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
